Author

G. Hoser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Klejman· 1 shared A. Kominek· 1 shared A. Piekielko-Witkowska· 1 shared D. Nowis· 1 shared E. Kozlowska· 1 shared F. Hornung· 1 shared I. Seferynska· 1 shared J. Golab· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Klejman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SARS-CoV-2 and its ORF3a, E and M viroporins activate inflammasome in human macrophages and induce of IL-1α in pulmonary epithelial and endothelial cells

M. Abrozek-Latecka, P. Kozlowski, G. Hoser, M. Bandyszewska, K. Hanusek, D. Nowis, J. Golab, M. Grzanka, A. Piekielko-Witkowska, L. Schulz, F. Hornung, S. Deinhardt-Emmer, E. Kozlowska, T. Skirecki

This study shows SARS-CoV-2 viroporins ORF3a, E, and M activate inflammasomes in macrophages and induce IL-1α release in pulmonary epithelial and endothelial cells, contributing to immunothrombosis in COVID-19.

bioRxiv · Nov 13, 2023 · PreprintImmunology

Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cells

W. Dudka, G. Hoser, S. S. Mondal, L. Turos-Korgul, J. Swatler, M. Kusio-Kobiałka, M. Wolczyk, A. Klejman, M. Brewinska-Olchowik, A. Kominek, M. Wiech, M. M. Machnicki, I. Seferynska, T. Stoklosa, K. Piwocka

This study shows that combining ISRIB with imatinib reduces STAT5 signaling and eliminates imatinib-resistant CML cells by altering transcriptomic profiles.

bioRxiv · May 5, 2021 · PreprintCancer Biology